ARCHIVES

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

This article is from The Cancer Letter archive.

Vol. 20 No. 33 | August 19, 1994

Download PDF Visit The Full Archive

Related Articles

GAO Probes NCI Intramural Program, Finds All Is Well, But Won’t Report It

October 22, 1982

Alan Rabson Named Acting NCI Director

October 5, 2001

Monitoring of Clinical Trials Finds Two Major Problems; Investigators Are Suspended

August 19, 1983

NCI Program Develops Bioinformatics Tool To Design Cancer Drugs

September 13, 2002

Bush Appoints Kripke To President’s Cancer Panel

March 21, 2003

Also In sudden policy change, NIH proposes one-year ban on consulting by employees.

October 1, 2004